معرفی
Abby E. Alpert is an Associate Professor of Health Care Management at the Wharton School of the University of Pennsylvania and a Faculty Research Fellow at the National Bureau of Economic Research. Her academic career spans health economics and public finance with a specialized focus on pharmaceutical market dynamics.
Dr. Alpert's research centers on two primary areas within pharmaceutical economics: the impacts of government intervention in pharmaceutical markets and the pharmaceutical industry's role in the opioid epidemic. Her work examines vertical integration effects in Medicare Part D, direct-to-consumer advertising consequences on drug utilization, and Medicaid policies affecting vulnerable populations' access to medications. She has made significant contributions to understanding the origins of the opioid crisis and evaluating supply-side policy interventions.
Analysis of Dr. Alpert's publication record reveals a consistent research trajectory focusing on pharmaceutical market regulation, with particular attention to pricing mechanisms, advertising effects, and policy interventions. Her work demonstrates strong methodological rigor in evaluating causal relationships within complex healthcare systems, often leveraging natural experiments and policy changes as identification strategies. The progression of her research shows increasing focus on the opioid epidemic and its multifaceted consequences.
Dr. Alpert's research has received substantial external funding from prestigious institutions including the National Institutes of Health and the Agency for Healthcare Research and Quality. Her findings have achieved significant public impact, being featured in major media outlets such as the New York Times, Washington Post, and The Economist, demonstrating the policy relevance of her work.
Prior to her current position at Wharton, Dr. Alpert served as an Assistant Professor of Economics and Public Policy at the University of California, Irvine's Paul Merage School of Business and as an Associate Economist at the RAND Corporation. She has advised multiple PhD students in health economics and policy evaluation, though specific names are not publicly listed in the available materials.
